Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
October 30, 2024 16:15 ET
|
Processa Pharmaceuticals, Inc.
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared with...
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
October 02, 2024 16:05 ET
|
Processa Pharmaceuticals, Inc.
Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to define...
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
September 03, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences...
Processa Pharmaceuticals Provides Product Pipeline and Financial Update
August 28, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri...
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
August 19, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 ...
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
July 30, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA)...
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
July 17, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
June 11, 2024 08:20 ET
|
Processa Pharmaceuticals, Inc.
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
May 06, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
April 30, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a...